IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
26.92
-0.57 (-2.07%)
At close: Oct 7, 2025, 4:00 PM EDT
26.92
0.00 (0.00%)
After-hours: Oct 7, 2025, 4:20 PM EDT
IDEAYA Biosciences Employees
IDEAYA Biosciences had 131 employees as of December 31, 2024. The number of employees increased by 7 or 5.65% compared to the previous year.
Employees
131
Change (1Y)
7
Growth (1Y)
5.65%
Revenue / Employee
$53,435
Profits / Employee
-$2,532,840
Market Cap
2.36B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131 | 7 | 5.65% |
| Dec 31, 2023 | 124 | 21 | 20.39% |
| Dec 31, 2022 | 103 | 22 | 27.16% |
| Dec 31, 2021 | 81 | 19 | 30.65% |
| Dec 31, 2020 | 62 | 15 | 31.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IDYA News
- 11 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences, Inc. (IDYA) 10-Year Anniversary R&D Day (Transcript) - Seeking Alpha
- 4 weeks ago - IDEAYA Biosciences: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst - Seeking Alpha
- 4 weeks ago - IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha